Cargando…
Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response
Metformin, a biguanide agent, is the first-line treatment for type 2 diabetes mellitus due to its glucose-lowering effect. Despite its wide application in the treatment of multiple health conditions, the glycemic response to metformin is highly variable, emphasizing the need for reliable biomarkers....
Autores principales: | Ustinova, Monta, Ansone, Laura, Silamikelis, Ivars, Rovite, Vita, Elbere, Ilze, Silamikele, Laila, Kalnina, Ineta, Fridmanis, Davids, Sokolovska, Jelizaveta, Konrade, Ilze, Pirags, Valdis, Klovins, Janis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418999/ https://www.ncbi.nlm.nih.gov/pubmed/32780768 http://dx.doi.org/10.1371/journal.pone.0237400 |
Ejemplares similares
-
Metformin strongly affects transcriptome of peripheral blood cells in healthy individuals
por: Ustinova, Monta, et al.
Publicado: (2019) -
Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients
por: Elbere, Ilze, et al.
Publicado: (2020) -
Novel susceptibility loci identified in a genome-wide association study of type 2 diabetes complications in population of Latvia
por: Ustinova, Monta, et al.
Publicado: (2021) -
Metformin Strongly Affects Gut Microbiome Composition in High-Fat Diet-Induced Type 2 Diabetes Mouse Model of Both Sexes
por: Silamiķele, Laila, et al.
Publicado: (2021) -
Association of metformin administration with gut microbiome dysbiosis in healthy volunteers
por: Elbere, Ilze, et al.
Publicado: (2018)